Management of incidental hepatitis C virus infection

New England Journal of Medicine

Volumn 360, Issue 18, 2009, Pages 1902-1906

  Afdhal, Nezam H ^a   Lok, Anna S F ^b   Di Bisceglie, Adrian M ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DEPRESSION; ELASTOGRAPHY; ETHNIC GROUP; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST RANGE; HUMAN; INCIDENTAL FINDING; LIVER BIOPSY; LIVER FIBROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE; RISK FACTOR; STAGING; VIRUS LOAD; ADULT; BIOPSY; BLOOD; CASE REPORT; FEMALE; GENETICS; IMMUNOLOGY; LIVER; PATHOLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BIOPSY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON ALFA-2A; LIVER; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 65449134731     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMclde0900131     Document Type: Letter

References (16)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832 (Pubitemid 27129209)
2. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002;36:973-977
3. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008;134:1670-1681
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
5. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477 (Pubitemid 44142464)
6. McHutchison JG, Everson GT, Gordon SC, et al. PROVE 1: results from a phase 2 study of telaprevir with peg-interferon alfa 2a and ribavirin in treatment naïve subjects with hepatitis C. J Hepatol 2008;48:s4. abstract.
7. Kwo P, Lawitz EJ, McCone J, et al. HCV SPRINT-1: bocepravir plus peg-interferon alfa 2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Hepatology 2008;48:1027A. abstract.
8. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171 [Erratum, Hepatology 2004;40:269.] (Pubitemid 38428955)
9. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-1732 (Pubitemid 39575851)
10. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350 (Pubitemid 40439195)
11. Thompson A, Patel K, Tillman H, McHutchison JG. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol 2009;50:184-194
12. Afdhal N. The natural history of hepatitis C. Semin Liver Dis 2004;24:Suppl 2:3-8. (Pubitemid 39180700)
13. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-2441
14. Puoti C, Castellacci R, Montagnese F, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002;37:117-123 (Pubitemid 34713063)
15. Mallet V, Gilgenkrantz H, Serpaggi J, et al. The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403. [Erratum, Ann Intern Med 2008;149:844.]
16. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684